News ACC25: Ozempic shows its value in PAD Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.
News Compounders cast adrift after semaglutide shortage ends The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.
Digital Looking beyond the scale: Why measures of physical activity ... GLP-1 receptor agonists like Ozempic and Wegovy are dramatically changing how healthcare professionals approach the treatment of obesity in patients.
News Novo rises on Wegovy sales leap, but warns of a slowdown Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.
News Ozempic is first GLP-1 drug FDA-approved for kidney disease Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.
News Ozempic tops new Medicare price negotiation list On their way out the door, the Biden administration has dropped the list of the next 15 drugs to be negotiated by Medicare.
Market Access New FDA head says no more pharma on advisory committees The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
